Skip Navigation
Department of Health and Human Services www.hhs.gov
 
This website is iPhone friendly.

This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201000006G from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.

Methods for Insulin Delivery and Glucose Monitoring in Diabetes: A Summary of Comparative Effectiveness Review

To Receive a Certificate for This Activity:

Course Image
  1. 1. Read the Program Overview on this page.
  2. 2. Review the Faculty Biographies, Accreditation Statements, and Disclosure tabs.
  3. 3. Access the Activity in full.
  4. 4. Complete the Post-Test & Evaluation.
  5. 5. A printable certificate will be available immediately following the activity.

Program Overview

Activity Description

Tight glycemic control with intensive insulin therapy has been suggested to reduce the risk of long-term complications in several diabetes populations; however, such an approach can also be associated with risks and challenges.

The Agency for Healthcare Research and Quality (AHRQ) commissioned a comparative effectiveness review of published studies to assess whether the mode of insulin delivery and/or the mode of blood glucose monitoring improves glycemic control, clinical outcomes, hypoglycemia and quality of life in patients with type 1 diabetes, type 2 diabetes, and pre-existing diabetes in pregnancy. This journal article summarizes the evidence obtained from the AHRQ systematic review to assist healthcare professionals in making informed decisions regarding insulin delivery and glucose monitoring systems in patients with diabetes.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Compare the benefits of insulin delivery systems in improving clinical outcomes, glycemic control, hypoglycemia and quality of life in diabetic patients receiving intensive insulin therapy
  • Evaluate the differential effect of glucose monitoring approaches on the process measures, intermediate and clinical outcomes in diabetic patients receiving intensive insulin therapy
  • Apply the AHRQ findings to guide effective, patient-centered clinical decisions

Target Audience

This CME activity is designed to meet the educational needs of physicians, pharmacists, nurses and case managers.

Method of Participation

To receive a certificate for this activity, you should:

  • Complete the learner assessment pretest
  • View the entire activity online
  • Complete an online evaluation & post-test
  • Print your certificate online

The estimated time to complete this activity, including review of the materials, is 1.0 hour.

Term of Approval

August 31, 2012 through September 30, 2013. Original release date: August 31, 2012

Acknowledgement of Support

There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201000006G from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).

Faculty Biographies and Disclosures

Click faculty name to view full biography.

Contributing Author

Sherita Hill Golden, MD, MHS, FAHA
Associate Professor of Medicine and Epidemiology Director
Inpatient Diabetes Management Service Chairperson
JHH Glucose Management Committee
Division of Endocrinology and Metabolism Welch Center for Prevention, Epidemiology, and Clinical Research
Johns Hopkins University School of Medicine
Co-Investigator with the Johns Hopkins Evidence-Based Practice Center
Baltimore, MD

Contributing Author

Tamar Sapir, PhD
Director of Scientific Affairs
PRIME Education, Inc.
Tamarac, FL

Planner

Michele B Kaufman, PharmD, BPharm, RPh
President
PRN Communications, Inc
Clinical Pharmacist
New York Downtown Hospital
New York, NY

Planner

Heidi Wynn Maloni, PhD, ANP-BC
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East
Veterans Affairs Medical Center
Adjunct Faculty
Trinity Nursing Program School of Professional Studies
Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs
The Catholic University of America School of Nursing
Washington, DC

Peer Reviewer

Debbie DeMuria, PharmD, RPh
Clinical Pharmacist
Consultant, Regulatory Affairs
Southborough, MA

Peer Reviewer

Sherman Podolsky, MD
Chief Medical Officer
Sunshine State Health Plan
Sunrise, FL
Former Chairman
Department of Emergency Medicine
Albert Einstein Medical Center
Philadelphia, PA

Peer Reviewer

Kathleen A Jarvis, MS, RN, CCM
Clinical Educator
Alere Healthcare
Fort Lauderdale, FL

Begin Activity

Accreditation/Credit Designation

Physician Credit Designation Statement

A C C M E Logo

PRIME Education, Inc. (PRIME®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

PRIME® designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation StatementA C P E Logo

This curriculum has been approved for 1.0 contact hour (0.1 CEUs) by PRIME®. PRIME® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is 0255-0000-12-033-H01-P. This learning activity is Knowledge-Based.

Nurse Accreditation StatementA N C C Logo

PRIME Education, Inc. (PRIME®) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

PRIME® designates this activity for 1.0 contact hour.

Case Manager Accreditation Statement

The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers.

Begin Activity

Faculty Disclosures

Faculty Name
Advisory Board Consultant Grants / Research Salary / Contractual Supported Promotional Education Stock / Shareholder Other Financial Support
Sherita Hill Golden, MD, MHS, FAHA
Planner
None None AHRQ None None None None
Tamar Sapir, PhD
Contributor
None None None None None None None
Michele B Kaufman, PharmD, BPharm, RPh
Planner
None OrthoMcNeil Janssen None None None None None
Heidi Wynn Maloni, PhD, ANP-BC
Planner
Sanofi-Aventis None None None None None None
Debbie DeMuria, PharmD, RPh
Reviewer
None Millenium Pharmaceuticals None None None None None
Sherman Podolsky, MD
Reviewer
None None None None None None None
Kathleen A Jarvis, MS, RN, CCM
Reviewer
None None None None None None None
Chris R Prostko, PhD
Scientific Program Director
NoneNoneNonePRIME®NoneNoneNone
Lynn Goldenberg, RN, BSN
Director of Accreditation & Compliance
NoneNoneNonePRIME®NoneNoneNone

Disclosure Policy

PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.

Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.

Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.

Accessibility

PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.

Begin Activity

Pretest

To access the activity, please complete this brief Pretest.

  • Returning user? Login Here!
  1. Before accessing this educational activity, were you aware of the AHRQ-supported comparative effectiveness research on insulin delivery and glucose monitoring methods for diabetes patients?

  2. Which of the following statements is true regarding the use of intensive insulin therapy to achieve tight glycemic control in diabetic patients?

  3. Which of the following statements is true regarding the use of blood glucose monitoring methods for patients with diabetes?

  4. How would you describe your current level of confidence in applying comparative effectiveness research on insulin delivery and glucose monitoring methods for diabetes patients?

  5. How valuable is comparative effectiveness research on insulin delivery and glucose monitoring methods for diabetes patients in making patient-centered treatment and management decisions?

  6. If you had a clinician guide/consumer guide on insulin delivery and glucose monitoring methods for diabetes patients, what would you most likely do?

  7. D is a 20-year-old female who was diagnosed with type 1 diabetes mellitus (T1DM) 10 years ago. She is currently receiving intensive insulin therapy by multiple daily injections (MDI) and self-monitors her blood glucose (SMBG) levels at least three times daily by fingerstick. As she is about to leave home to pursue her graduate studies, she is concerned how she would maintain her glycemic goals in midst of the changes in her lifestyle and social life. She is meeting with her clinician to discuss alternative available insulin delivery and glucose monitoring modalities. Which of the following statements from the AHRQ review regarding the insulin delivery and glucose monitoring methods for diabetic patients are correct and most appropriate when consulting D for available options to manage her T1DM?

Post-Test & Evaluation

You must access the activity before receiving credit!

Clinician & Consumer Summaries on Insulin Delivery and Glucose Monitoring

Download these free summaries for your reference and/or patient handouts. You may also order bulk copies free of charge from the AHRQ Publication Clearinghouse below.

AHRQ Clearinghouse Bulk Order Form

Returning user? Login Here
  • (Limit 200)
  • (This answer helps stop spam )
  • Alternatively, you can call the AHRQ Publications Clearinghouse at 1-800-358-9295. Reference the title and product number above.